Michael E. Hart
Director/Board Member at Affygility Solutions
Profile
Michael Hart joined Allos in 1999 and was promoted to president and chief executive officer in December 2001 and to the board of directors in April 2002.
Prior to his promotion, he was chief financial officer and senior vice president of operations.
From 1998 to 1999, Mr. Hart served as chairman of the management committee of NeXstar Pharmaceuticals, Inc. and led the sale of the company to Gilead Sciences in July 1999.
From 1990 to 1998, Mr. Hart served as vice president, chief financial officer of NeXstar Pharmaceuticals Inc. and its predecessor Vestar, Inc. During his tenure, Mr. Hart was instrumental in building an international organization that supported $120 million in product revenues in over 30 countries around the world.
During this period he also helped successfully guide NeXstar through two company acquisitions and several product approvals.
Between 1976-1990, Mr. Hart held various financial positions with several high technology companies in the Silicon Valley.
Mr. Hart received his M.B.A.
from California State University, Fresno, and his undergraduate degrees in business economics and geography from the University of California, Santa Barbara.
Michael E. Hart active positions
| Companies | Position | Start |
|---|---|---|
Affygility Solutions
 Affygility Solutions Miscellaneous Commercial ServicesCommercial Services Affygility Solutions is a private company that provides occupational health, safety, and toxicology services to the life science industry. The company is based in Broomfield, CO and was founded in 2002. The company's services include the Affytrac EH&S management tool, potent compound safety and categorization, occupational exposure limits, and acceptable daily exposure limits for active pharmaceutical ingredients, and genotoxic impurity evaluations. The company has provided these services to small, mid-size, and large life science companies in over 65 different countries. The CEO is Dean Calhoun. | Director/Board Member | - |
Former positions of Michael E. Hart
| Companies | Position | End |
|---|---|---|
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Chief Executive Officer | 08/03/2006 |
Training of Michael E. Hart
| California State University-Fresno | Masters Business Admin |
| University of California, Santa Barbara | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Affygility Solutions
Affygility Solutions Miscellaneous Commercial ServicesCommercial Services Affygility Solutions is a private company that provides occupational health, safety, and toxicology services to the life science industry. The company is based in Broomfield, CO and was founded in 2002. The company's services include the Affytrac EH&S management tool, potent compound safety and categorization, occupational exposure limits, and acceptable daily exposure limits for active pharmaceutical ingredients, and genotoxic impurity evaluations. The company has provided these services to small, mid-size, and large life science companies in over 65 different countries. The CEO is Dean Calhoun. | Commercial Services |
- Stock Market
- Insiders
- Michael E. Hart